Ezetimibe and Cognitive Function: Emerging Signals Beyond Lipid Lowering

Ezetimibe has long been viewed as a straightforward adjunct to statin therapy—an inhibitor of intestinal cholesterol absorption via NPC1L1, useful for lowering LDL-C with minimal systemic effects. But recent data suggest a more complex story may be unfolding, with potential implications for brain health and neurodegenerative disease.

From Lipids to the Brain: Why This Matters

Cholesterol metabolism is tightly intertwined with neurobiology. Dysregulated lipid homeostasis has been implicated in:

• Amyloid-beta aggregation

• Tau pathology

• Neuronal energy dysfunction

• Synaptic integrity

While statins have historically dominated discussions around lipid-lowering and cognition, ezetimibe’s distinct mechanism raises the possibility of non-overlapping—and potentially complementary—effects.

A Novel Mechanistic Signal

A 2024 mechanistic and clinical study (Ganne et al., Aging Biology) identified a striking pathway:

• Ezetimibe disrupts the 14-3-3γ–hexokinase-1 (HK1) interaction

• This interaction is implicated in protein aggregation in Alzheimer’s disease

• Disruption led to:

  • Reduced aggregation of pathological proteins

  • Activation of autophagy pathways

  • Improved cellular resilience in multiple experimental models

This suggests ezetimibe may influence core proteostasis mechanisms, not just lipid levels.

Human Data: A Surprisingly Strong Signal

In a large observational analysis of approximately 950,000 older adults, ezetimibe use was associated with a markedly reduced incidence of Alzheimer’s disease and related dementias (ADRD):

• Relative risk: 0.14 (95% CI 0.06–0.34)

• Roughly a 7-fold reduction in risk

• In patients with coronary artery disease:

  • RR ~0.12 (~8-fold reduction)

Notably, this was described as the strongest protective association among studied pharmacologic interventions in that dataset.

However, this remains observational data—a critical limitation when interpreting magnitude of effect.

Translational Support: Animal and Genetic Evidence

Preclinical models

Across multiple studies:

• Mouse models (2009–2010):

  • Reversal of memory deficits

  • Improvement in biochemical markers of neurodegeneration

• Rat models (2016):

  • Reduced amyloid plaques and tau aggregates

  • Increased IGF-1 receptor expression

  • Improved spatial memory and recognition

These findings suggest both cholesterol-dependent and independent mechanisms.

Genetic (Mendelian Randomization) Insights

Genetic variants that mimic NPC1L1 inhibition (the target of ezetimibe) have been associated with:

• Lower risk of dementia

• Broader support for a link between LDL-C reduction and neuroprotection

Some large-scale analyses (>1 million individuals) suggest up to substantial reductions in dementia risk with lipid-lowering pathways.

Clinical Trial Reality

• Large cardiovascular trials and meta-analyses show:

  • No significant adverse cognitive effects

  • No consistent signal for memory impairment

• Ezetimibe remains:

  • Well tolerated

  • Widely used

  • Mechanistically distinct from statins

Crucially:

No randomized controlled trials have evaluated ezetimibe for cognition or dementia prevention.

Interpreting the Signal

Taken together:

What looks promising:

• Strong mechanistic plausibility

• Converging preclinical evidence

• Large observational signal

What limits interpretation:

• Observational design (confounding, bias)

• Conflicting genetic and comparative data

• Absence of prospective cognitive endpoints

Bottom Line

Ezetimibe may represent more than a lipid-lowering agent. Early evidence suggests potential involvement in protein aggregation, autophagy, and neurodegeneration pathways, with a striking—but unproven—association with reduced dementia risk.

At present:

• It is not a cognitive therapy

• It remains a cardiovascular drug with an excellent safety profile

• Its neurological effects are hypothesis-generating, not practice-changing

Where This Is Going

The next step is clear:

• Prospective randomized trials with cognitive endpoints

• Better understanding of NPC1L1 biology in the CNS

• Comparative studies across lipid-lowering pathways (statins vs ezetimibe vs PCSK9 inhibitors)

Until then, ezetimibe sits in an interesting position:

A simple drug with unexpectedly complex biology—and a signal worth paying attention to.